After 28 days of treatment, BL1107 did not meet its main goal of improving visual field scores in a study.

July 9 (Reuters) - Bausch + Lomb said on Thursday its glaucoma eye drop had missed the main goal in a mid-stage trial of ...

Bausch + Lomb will stop developing a topical eye drop for glaucoma after the drug failed to meet its primary endpoint in a phase 2 study. The company on Thursday said the drug, BL1107, didn't ...

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 3.8% in the afternoon session after the company announced its ...

Eyecare company Bausch + Lomb has had a hole blown in its pharma pipeline, after disappointing trial results forced it to ...

Bausch + Lomb has abandoned its next great hope in glaucoma after the eye drops flunked a phase 2 study. The eye health company had been evaluating the alpha-2B agonist, dubbed BL1107, in a mid-stage ...

Bausch + Lomb (BLCO) is in focus after two product updates: a discontinued glaucoma eye drop program for BL1107 and the ...

Glaucoma may be managed with medicated eye drops, laser procedures, and surgery to slow progression and reduce the risk of vision loss. Medicated eye drops, including prostaglandins and beta-blockers, ...

Thank you for signing up! Did you know with a Digital Subscription to The Scotsman, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, ...

Glaucoma is one of the three leading causes of blindness in Germany and worldwide. This neurodegenerative disease progressively damages the retinal nerve fibres, leading to irreversible vision loss.

Glaucoma impacts the vision of more than 3 million Americans, increasing the pressure in the eye, damaging the optic nerve and, if left untreated, causing permanent damage and vision loss. Until now, ...

Using pilocarpine eye drops following Kahook Dual Blade (KDB) goniotomy surgery may improve clinical outcomes for patients with glaucoma and reduce the need for future medications, according to new ...